5 apos; situally modified nucleosides and nucleotides using the same

By introducing 5' modified nucleosides of the cyclopentene structure at 5' position, the problems of insufficient double-strand formation ability and synthesis complexity of target RNA in the prior art are solved, and efficient and simplified development of nucleic acid drugs are achieved. High enzyme tolerance and simplified synthesis process solutions.

CN118946575APending Publication Date: 2024-11-12OSAKA UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380024526.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-11
Filing Date
2023-02-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing 5' modified nucleosides are insufficient in the double-strand formation ability of target RNA and need to isolate diastereoisomers during the synthesis process, resulting in complex manufacturing and affecting their application in nucleic acid medicine.

Method used

A 5' modified nucleoside without the need to isolate diastereoisomers was developed, which improves nuclease tolerance and enhances the double-strand formation ability of target RNA by introducing cyclopentene structures at 5'. lylic acid, oligonucleotides are produced by specific synthetic methods such as phosphoramidite method.

Benefits of technology

Achieve excellent double-strand formation ability and enzyme tolerance in pharmaceutical development, simplify the synthesis process, reduce production complexity, and provide equivalent or higher nuclease resistance as a substitute for phosphorothioate modified nucleic acids Receptive.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946575A_ABST
    Figure CN118946575A_ABST
Patent Text Reader

Abstract

The invention discloses a 5'modified nucleoside and a nucleotide using the 5 'modified nucleoside. A nucleoside according to the present invention is a compound represented by formula (I) or a salt thereof. The nucleoside according to the present invention has an appropriate double-strand formation ability with respect to a target RNA and excellent nuclease resistance, does not require a diastereoisomer isolation operation in the synthesis route thereof, and can be efficiently produced. The nucleoside according to the present invention can also replace a thiophosphate-modified nucleic acid which is worried about accumulation or the like in a specific organ, and has excellent industrial productivity. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a 5'-modified nucleoside and a nucleotide using the 5'-modified nucleoside. More specifically, the present invention relates to a 5'-modified nucleoside that has appropriate double-strand forming ability and excellent nuclease resistance and can be efficiently produced and a nucleotide using the 5'-modified nucleoside. Background Art

[0002] Various artificial nucleic acids have been developed as raw materials for nucleic acid medicines. Among them, 2′,4′-BNA (bridged nucleic acid, also known as LNA), which immobilizes the sugar conformation of nucleic acid by cross-linking, has been reported to have excellent binding affinity to single-stranded RNA (ssRNA) (Non-patent Documents 1 and 2), and is expected to be used in various nucleic acid medicines such as antisense methods.

[0003] On the other hand, artificial nucleic acids with a methyl group introduced at the 5' position of nucleic acids have been reported to have excellent properties in terms of nuclease resistance (Patent Documents 1 to 3). Therefore, the application of artificial nucleic acids with a substituent introduced at the 5' position in diagnosis or medicine is also expected. However, such artificial nucleic acids require separation of diastereomers during their synthesis (Non-Patent Documents 3 and 4), so the overall manufacturing process becomes complicated.

[0004] In contrast, in recent years, artificial nucleic acids that do not require separation of diastereoisomers and that have a predetermined cyclopropane structure introduced at the 5′ position (hereinafter sometimes referred to as “5′-cp modified nucleic acid” or simply “5′-cp”) have been proposed (Patent Document 4). 5′-cp modified nucleic acids have the same or better enzyme resistance than thiophosphate modified nucleic acids (Non-Patent Document 5) that are currently used in the development of nucleic acid medicines, and are expected to be used as an alternative to thiophosphate modified nucleic acids that have been shown to be associated with hepatotoxicity.

[0005] However, the 5′-cp modified nucleic acid cannot, for example, satisfy the ability to form a double strand with respect to a target RNA, and further improvement is desired.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: International Publication No. 2010 / 048549

[0009] Patent Document 2: International Publication No. 2010 / 048585

[0010] Patent Document 3: International Publication No. 2010 / 077578

[0011] Patent Document 4: International Publication No. 2020 / 158910

[0012] Non-patent literature

[0013] Non-patent literature 1: S. Obika et al., T. Tetrahedron Lett. 1997, 38, 8735-8738.

[0014] Non-patent literature 2: S. Singh et al., J. Chem. Commun. 1998, 455-456.

[0015] Non-patent literature 3: A. M. Yawman et al., J. Org. Chem. 1995, 60, 788-789.

[0016] Non-patent document 4: M. Manoharan et al., J. Org. Chem. 2016, 81, 2261-2279.

[0017] Non-patent document 5: ST Crooke et al., J. Am. Chem. Soc. 2020, 142, 14754-15771. Summary of the invention

[0018] Technical problem to be solved by the invention

[0019] The present invention is an invention for solving the above-mentioned technical problems, and its purpose is to provide a 5′-modified nucleoside and a nucleotide using the nucleoside, which have appropriate double-strand forming ability for target RNA and excellent nuclease resistance and can be efficiently produced without requiring the operation of separating diastereomers in its synthesis route.

[0020] Technical solutions for solving technical problems

[0021] The present invention is a compound represented by the following formula (I) or a salt thereof:

[0022]

[0023] (In formula (I),

[0024] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0025] R 1 and R 2Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 [Where R 9 and R 10 [respectively independently represent a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms],

[0026] R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms,

[0027] R 5 and R 6 is a hydrogen atom, or R 5 and R 6 Together they form a single bond,

[0028] R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 [Where R 11 a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0029] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0030] In one embodiment, the above formula (I) is represented by the following formula (Ia):

[0031]

[0032] (In formula (Ia),

[0033] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0034] R 1 and R 2 Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 [Where R 9 and R 10 [respectively independently represent a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms],

[0035] R 3 and R 4 are each independently a hydrogen atom or an alkyl group having 1 or 2 carbon atoms,

[0036] R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 [Where R 11 a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0037] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0038] In one embodiment, the above formula (I) is represented by the following formula (Ib):

[0039]

[0040] (In formula (Ib),

[0041] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0042] R 1 and R 2 Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 [Where R 9 and R 10 [respectively independently represent a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms],

[0043] R 3 and R 4 are each independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms,

[0044] R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR11 [Where R 11 a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0045] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0046] In one embodiment, in the above formula (I), the above Base is 6-aminopurine-9-yl, 2,6-diaminopurine-9-yl, 2-amino-6-chloropurine-9-yl, 2-amino-6-fluoropurine-9-yl, 2-amino-6-bromopurine-9-yl, 2-amino-6-hydroxypurine-9-yl, 6-amino-2-methoxypurine-9-yl, 6-amino-2-chloropurine-9-yl, 6-amino-2-fluoropurine-9-yl, 2,6-dimethoxypurine-9-yl, 2,6-dichloropurine-9-yl, 6-mercaptopurine-9-yl, 2-oxypurine-9-yl, 2-oxo-4-thiol-1,2-dihydropyrimidin-1-yl, 2-oxo-4-hydroxy-1,2-dihydropyrimidin-1-yl, 2-oxo-4-hydroxy-5-methyl-1,2-dihydropyrimidin-1-yl, or 4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl.

[0047] In one embodiment, in the above formula (I), the above Base is a group represented by the following formula:

[0048]

[0049] The present invention also provides an oligonucleotide containing at least one nucleoside structure represented by the following formula (II) or a pharmacologically acceptable salt thereof:

[0050]

[0051] (In formula (II),

[0052] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0053] R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms,

[0054] R 5 and R 6 is a hydrogen atom, or R 5 and R 6 Together they form a single bond,

[0055] R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 [Where R 11 a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0056] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0057] In one embodiment, the above formula (II) is represented by the following formula (IIa):

[0058]

[0059] (In formula (IIa),

[0060] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0061] R 3 and R 4 are each independently a hydrogen atom or an alkyl group having 1 or 2 carbon atoms,

[0062] R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 [Where R 11a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0063] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0064] In one embodiment, the above formula (II) is represented by the following formula (IIb):

[0065]

[0066] (In formula (IIb),

[0067] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0068] R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms,

[0069] R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 [Where R 11 a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0070] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0071] The present invention also provides a method for producing the above-mentioned oligonucleotide or a pharmacologically acceptable salt thereof, comprising the step of synthesizing the oligonucleotide using a compound represented by the following formula (I) or a salt thereof,

[0072]

[0073] (In formula (I),

[0074] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0075] R 1 and R 2 Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 [Where R 9 and R 10 [respectively independently represent a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms],

[0076] R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms,

[0077] R 5 and R 6 is a hydrogen atom, or R 5 and R 6 Together they form a single bond,

[0078] R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 [Where R 11a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0079] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0080] Effects of the Invention

[0081] According to the present invention, a 5'-modified nucleoside having excellent double-strand forming ability and enzyme resistance and a nucleotide using the 5'-modified nucleoside that can be used in the development of pharmaceuticals is provided. The 5'-modified nucleoside of the present invention can also be used as a substitute for phosphorothioate-modified nucleic acids that are concerned about accumulation in specific organs. The 5'-modified nucleoside of the present invention also has excellent industrial productivity because it does not require a diastereoisomer separation step in its production. BRIEF DESCRIPTION OF THE DRAWINGS

[0082] Figure 1 The figure shows the evaluation of the resistance of five types of oligonucleotides (PO (native), PS, cp, cp2nd, cp3rd) to enzymes (3′-exonuclease). The upper left column shows a schematic diagram of 3′-exonuclease and the sequence used in the test, the lower left column shows a graph showing the evaluation results, and the right column shows the sequence of each oligonucleotide used in the test. T Diagram of the structure of the (artificial) nucleic acid carried on the part.

[0083] Figure 2 This is a graph showing the results of the inhibitory effect of the test oligonucleotide on the target gene (GR (NR3C1)). The results are expressed as mean ± standard error (SE).

[0084] Figure 3 This is a graph showing the evaluation results of AST (U / L) and ALT (U / L) in the blood of each test oligonucleotide administration group. The results are shown as mean ± standard error (SE). DETAILED DESCRIPTION

[0085] First, the terms used in this specification are defined.

[0086] In the present specification, the term "straight-chain alkyl group having 1 to 6 carbon atoms" refers to any straight-chain alkyl group having 1 to 6 carbon atoms, specifically, methyl, ethyl, n-propyl, n-butyl, n-pentyl or n-hexyl. On the other hand, when the term "alkyl group having 1 to 6 carbon atoms" is used, it refers to any straight-chain, branched or cyclic alkyl group having 1 to 6 carbon atoms.

[0087] In the present specification, the term "straight-chain alkoxy group having 1 to 6 carbon atoms" includes an alkoxy group having any straight-chain alkyl group having 1 to 6 carbon atoms. Examples thereof include methoxy, ethoxy, n-propoxy, and the like. On the other hand, in the case of the term "alkoxy group having 1 to 6 carbon atoms", it refers to any straight-chain, branched, or cyclic alkoxy group having 1 to 6 carbon atoms. In addition, in the case of the term "straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms", it refers to the above-mentioned "straight-chain alkoxy group having 1 to 6 carbon atoms" and an alkoxy group in which one or more hydrogen atoms constituting the "straight-chain alkoxy group having 1 to 6 carbon atoms" are substituted by the same or different other "straight-chain alkoxy groups having 1 to 6 carbon atoms". Examples of such “straight-chain alkoxy groups having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms” include methoxy, ethoxy, n-propoxy, methoxymethoxy, ethoxymethoxy, n-propoxymethoxy, methoxyethoxy (e.g., 2-methoxyethoxy), ethoxyethoxy (e.g., 2-ethoxyethoxy), and n-propoxyethoxy.

[0088] In the present specification, the term "cyanoalkoxy group having 1 to 6 carbon atoms" refers to a group in which at least one hydrogen atom in any linear, branched or cyclic alkoxy group having 1 to 6 carbon atoms is substituted with a cyano group.

[0089] In the present specification, the term "linear alkylthio group having 1 to 6 carbon atoms" includes an alkylthio group having any linear alkyl group having 1 to 6 carbon atoms. Examples thereof include methylthio, ethylthio, n-propylthio, etc. On the other hand, when the term "alkylthio group having 1 to 6 carbon atoms" is used, it refers to any linear, branched or cyclic alkylthio group having 1 to 6 carbon atoms.

[0090] In the present specification, the term "linear alkylamino group having 1 to 6 carbon atoms" includes alkylamino groups having one or two alkylamino groups having any linear alkyl group having 1 to 6 carbon atoms. Examples thereof include methylamino, dimethylamino, ethylamino, methylethylamino, and diethylamino.

[0091] In the present specification, the term "alkyl group having 1 to 7 carbon atoms which may form a branch or a ring" includes any straight-chain alkyl group having 1 to 7 carbon atoms, any branched-chain alkyl group having 3 to 7 carbon atoms, and any cyclic alkyl group having 3 to 7 carbon atoms. It is sometimes also referred to as "lower alkyl group". For example, as any straight-chain alkyl group having 1 to 7 carbon atoms, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and n-heptyl can be listed, as any branched-chain alkyl group having 3 to 7 carbon atoms, isopropyl, isobutyl, tert-butyl, isopentyl and the like can be listed, and as any cyclic alkyl group having 3 to 7 carbon atoms, cyclobutyl, cyclopentyl, cyclohexyl and the like can be listed.

[0092] In the present specification, the term "alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring" includes any straight-chain alkenyl group having 2 to 7 carbon atoms, any branched alkenyl group having 3 to 7 carbon atoms, and any cyclic alkenyl group having 3 to 7 carbon atoms. It is sometimes also referred to as "lower alkenyl group". For example, examples of any straight-chain alkenyl group having 2 to 7 carbon atoms include ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, and 1-hexenyl. Examples of any branched alkenyl group having 3 to 7 carbon atoms include isopropenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, and 1-methyl-2-butenyl. Examples of any cyclic alkenyl group having 3 to 7 carbon atoms include cyclobutenyl, cyclopentenyl, and cyclohexenyl.

[0093] In the present specification, the term "aryl group having 3 to 10 carbon atoms which may contain heteroatoms" includes any aryl group having 6 to 10 carbon atoms which is composed only of hydrocarbons, and any heteroaryl group having 3 to 12 carbon atoms in which at least one carbon atom constituting the ring structure of the aryl group is substituted with a heteroatom (e.g., a nitrogen atom, an oxygen atom, a sulfur atom, and a combination thereof). Examples of the aryl group having 6 to 10 carbon atoms include phenyl, naphthyl, indenyl, azulenyl, and the like, and examples of the heteroaryl group having 3 to 12 carbon atoms include pyridyl, pyrrolyl, quinolyl, indolyl, imidazolyl, furanyl, thienyl, and the like.

[0094] In the present specification, examples of the term "aralkyl group having an aryl moiety having 3 to 12 carbon atoms which may contain a heteroatom" include benzyl, phenethyl, naphthylmethyl, 3-phenylpropyl, 2-phenylpropyl, 4-phenylbutyl, 2-phenylbutyl, pyridylmethyl, indolylmethyl, furanylmethyl, thienylmethyl, pyrrolylmethyl, 2-pyridylethyl, 1-pyridylethyl, 3-thienylpropyl and the like.

[0095] In the present specification, examples of the term "acyl group" include aliphatic acyl groups and aromatic acyl groups. Specifically, examples of aliphatic acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl, isovaleryl, octanoyl, nonanoyl, decanoyl, 3-methylnonanoyl, 8-methylnonanoyl, 3-ethyloctanoyl, 3,7-dimethyloctanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, 1-methylpentadecanoyl, 14-methylpentadecanoyl, 1 ... The present invention also includes alkylcarbonyl groups such as pentadecanoyl, 13,13-dimethyltetradecanoyl, heptadecanoyl, 15-methylhexadecanoyl, octadecanoyl, 1-methylheptadecanoyl, nonadecanoyl, eicosanoyl and heneicosanoyl; carboxylated alkylcarbonyl groups such as succinyl, glutaryl and adipoyl; halogenated lower alkylcarbonyl groups such as chloroacetyl, dichloroacetyl, trichloroacetyl and trifluoroacetyl; lower alkoxy lower alkylcarbonyl groups such as methoxyacetyl; and unsaturated alkylcarbonyl groups such as (E)-2-methyl-2-butenoyl. Examples of aromatic acyl groups include arylcarbonyl groups such as benzoyl, α-naphthoyl, and β-naphthoyl; halogenated arylcarbonyl groups such as 2-bromobenzoyl and 4-chlorobenzoyl; lower alkylated arylcarbonyl groups such as 2,4,6-trimethylbenzoyl and 4-toluoyl; lower alkoxylated arylcarbonyl groups such as 4-anisyl; carboxylated arylcarbonyl groups such as 2-carboxybenzoyl, 3-carboxybenzoyl, and 4-carboxybenzoyl; nitrolated arylcarbonyl groups such as 4-nitrobenzoyl and 2-nitrobenzoyl; lower alkoxycarbonylated arylcarbonyl groups such as 2-(methoxycarbonyl)benzoyl; and arylated arylcarbonyl groups such as 4-phenylbenzoyl. Preferred are formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, and benzoyl.

[0096] In the present specification, examples of the term "silyl group" include trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, tert-butyldimethylsilyl, methyldiisopropylsilyl, methyldi-tert-butylsilyl, triisopropylsilyl and other tri-lower alkylsilyl groups; diphenylmethylsilyl, butyldiphenylbutylsilyl, diphenylisopropylsilyl, phenyldiisopropylsilyl and other tri-lower alkylsilyl groups substituted with 1 to 2 aryl groups. Preferred are trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl and tert-butyldiphenylsilyl, and more preferably trimethylsilyl.

[0097] In the present specification, the term "halogen atom" includes, for example, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, preferably a fluorine atom or a chlorine atom.

[0098] In the present specification, the term "protecting group for amino group in nucleic acid synthesis", "protecting group for hydroxyl group in nucleic acid synthesis", "hydroxyl group protected by protective group in nucleic acid synthesis", "phosphate group protected by protective group in nucleic acid synthesis", "thiol group protected by protective group in nucleic acid synthesis" is not particularly limited as long as it is a group that can stably protect amino group, hydroxyl group, phosphate group or thiol group during nucleic acid synthesis. Specifically, it refers to a protecting group that is stable under acidic or neutral conditions and can be cleaved by chemical methods such as hydrogenolysis, hydrolysis, electrolysis and photolysis. Examples of such protecting groups include lower alkyl, lower alkenyl, acyl, tetrahydropyranyl or tetrahydrothiopyranyl, tetrahydrofuranyl or tetrahydrothiofuranyl, silyl, lower alkoxymethyl, lower alkoxylated lower alkoxymethyl, halogenated lower alkoxymethyl, lower alkoxylated ethyl, halogenated ethyl, methyl substituted with 1 to 3 aryl groups, "methyl substituted with 1 to 3 aryl groups whose aryl ring is substituted with a lower alkyl, lower alkoxy, halogen atom or cyano group", lower alkoxycarbonyl, "aryl substituted with a halogen atom, lower alkoxy or nitro group", "lower alkoxycarbonyl substituted with a halogen atom or a tri-lower alkylsilyl group", alkenyloxycarbonyl, "aralkyloxycarbonyl whose aryl ring may be substituted with a lower alkoxy or nitro group", and the like.

[0099] More specifically, examples of tetrahydropyranyl or tetrahydrothiopyranyl include tetrahydropyran-2-yl, 3-bromotetrahydropyran-2-yl, 4-methoxytetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, and 4-methoxytetrahydrothiopyran-4-yl. Examples of tetrahydrofuranyl or tetrahydrothiofuranyl include tetrahydrofuran-2-yl and tetrahydrothiofuran-2-yl. Examples of lower alkoxymethyl include methoxymethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl, and tert-butoxymethyl. Examples of lower alkoxylated lower alkoxymethyl include 2-methoxyethoxymethyl. Examples of halogenated lower alkoxymethyl include 2,2,2-trichloroethoxymethyl and bis(2-chloroethoxy)methyl. Examples of lower alkoxylated ethyl include 1-ethoxyethyl and 1-(isopropoxy)ethyl. Examples of the halogenated ethyl group include 2,2,2-trichloroethyl. Examples of the methyl group substituted with 1 to 3 aryl groups include benzyl, α-naphthylmethyl, β-naphthylmethyl, diphenylmethyl, triphenylmethyl, α-naphthyldiphenylmethyl, 9-anthrylmethyl, etc. Examples of the “methyl group substituted with 1 to 3 aryl groups whose aryl ring is substituted with a lower alkyl group, a lower alkoxy group, a halogen atom or a cyano group” include 4-methylbenzyl, 2,4,6-trimethylbenzyl, 3,4,5-trimethylbenzyl, 4-methoxybenzyl, 4-methoxyphenyldiphenylmethyl, 4,4′-dimethoxytriphenylmethyl, 2-nitrobenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-bromobenzyl, 4-cyanobenzyl, etc. Examples of the lower alkoxycarbonyl group include methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, isobutoxycarbonyl, etc. Examples of the "aryl group substituted with a halogen atom, a lower alkoxy group or a nitro group" include 4-chlorophenyl, 2-chlorophenyl, 4-methoxyphenyl, 4-nitrophenyl, and 2,4-dinitrophenyl. Examples of the "lower alkoxycarbonyl group substituted with a halogen atom or a tri-lower alkylsilyl group" include 2,2,2-trichloroethoxycarbonyl and 2-trimethylsilylethoxycarbonyl. Examples of the alkenyloxycarbonyl group include vinyloxycarbonyl and aryloxycarbonyl. Examples of the "aralkyloxycarbonyl group whose aryl ring may be substituted with a lower alkoxy group or a nitro group" include benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, and 4-nitrobenzyloxycarbonyl.

[0100] In one embodiment, examples of the "protecting group for the hydroxyl group in nucleic acid synthesis" include aliphatic acyl groups, aromatic acyl groups, methyl groups substituted with 1 to 3 aromatic groups, "methyl groups substituted with 1 to 3 aromatic groups whose aromatic rings are substituted with lower alkyl groups, lower alkoxy groups, halogen groups or cyano groups", and silyl groups. Alternatively, in one embodiment, examples of the “protecting group for a hydroxyl group in nucleic acid synthesis” include acetyl, benzoyl, benzyl, p-methoxybenzoyl, dimethoxytrityl, monomethoxytrityl, tert-butyldiphenylsilyl, tert-butyldimethylsilyl (TBDMS), [(triisopropylsilyl)oxy]methyl (TOM), [(2-nitrobenzyl)oxy]methyl (NBOM), bis(acetoxyethoxy)methylether (ACE), tetrahydro-4-methoxy-2H-pyran-2-yl (Mthp), 1-(2-cyanoethoxy)ethyl (CEE), 2-cyanoethoxymethyl (CEM), tert-butyldithiomethyl (DTM), 2-(4-toluenesulfonyl)ethoxymethyl (TEM), and 4-(N-dichloroacetyl-N-methylamino)benzyloxymethyl (4-MABOM).

[0101] In one embodiment, examples of the protecting group for the "hydroxyl group protected by a protecting group for nucleic acid synthesis" include aliphatic acyl, aromatic acyl, "methyl substituted by 1 to 3 aryl groups", "aryl substituted by a halogen atom, a lower alkoxy group or a nitro group", lower alkyl and lower alkenyl. Alternatively, in one embodiment, examples of the protecting group for the "hydroxyl group protected by a protecting group for nucleic acid synthesis" include benzoyl, benzyl, 2-chlorophenyl, 4-chlorophenyl and 2-propenyl.

[0102] In one embodiment, examples of the "protecting group for the amino group in nucleic acid synthesis" include acyl groups, and preferably benzoyl groups.

[0103] In one embodiment, examples of the "protecting group" of the "phosphate group protected by a protecting group for nucleic acid synthesis" include lower alkyl groups, lower alkyl groups substituted with cyano groups, aralkyl groups, "aralkyl groups in which an aryl ring is substituted with a nitro group or a halogen atom", and "aryl groups substituted with a lower alkyl group, a halogen atom or a nitro group". Alternatively, in one embodiment, examples of the "protecting group" of the "phosphate group protected by a protecting group for nucleic acid synthesis" include 2-cyanoethyl, 2,2,2-trichloroethyl, benzyl, 2-chlorophenyl and 4-chlorophenyl.

[0104] In one embodiment, examples of the "protecting group" of the "thiol group protected by a protecting group for nucleic acid synthesis" include aliphatic acyl groups and aromatic acyl groups, and preferably benzoyl groups.

[0105] In this specification, -P(R 4 )R5 [Where R 4 and R 5 wherein each independently represents a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms], R 4 OR 4a And R 5 NR 5a The group refers to a "phosphoramidite group" (where R 4a For example, it is a cyanoalkoxy group having 1 to 6 carbon atoms, and R 5a For example, it is an alkyl group having 1 to 6 carbon atoms.) As the phosphoramidite group, preferably, a group represented by the formula -P(OC2H4CN)(N(iPr)2) or a group represented by the formula -P(OCH3)(N(iPr)2) is mentioned. Here, iPr represents an isopropyl group.

[0106] In the present specification, the terms "nucleoside" and "nucleoside analogs" refer to non-natural nucleosides among "nucleosides" formed by a purine or pyrimidine base bonded to a sugar, and substances formed by a substance in an aromatic heterocycle or aromatic hydrocarbon ring other than purine and pyrimidine that can serve as a substitute for a purine or pyrimidine base bonded to a sugar.

[0107] In the present specification, the terms "artificial oligonucleotide" and "oligonucleotide analogs" refer to non-natural derivatives of "oligonucleotides" in which, for example, 2 to 50 identical or different "nucleosides" or "nucleoside analogs" are linked by phosphodiester bonds. Such analogs preferably include sugar derivatives in which the sugar moiety is modified; thioester derivatives in which the phosphodiester moiety is thioated; esters in which the terminal phosphate moiety is esterified; and amides in which the amino group on the purine base is amidated. More preferably, sugar derivatives in which the sugar moiety is modified are included.

[0108] In the present specification, the term "salt thereof" refers to a salt of the compound represented by formula (I) of the present invention. As such salts, for example, alkali metal salts such as sodium salts, potassium salts, and lithium salts, alkaline earth metal salts such as calcium salts and magnesium salts, metal salts such as aluminum salts, iron salts, zinc salts, copper salts, nickel salts, and cobalt salts; inorganic salts such as ammonium salts, tert-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucosamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzyl-phenylethylamine salts, piperazine salts, tetramethylammonium salts, tris(hydroxymethyl) ) amine salts such as organic salts such as aminomethane salts; hydrohalide salts such as hydrofluoride, hydrochloride, hydrobromide, and hydroiodide, inorganic acid salts such as nitrate, perchlorate, sulfate, and phosphate; lower alkane sulfonates such as methanesulfonate, trifluoromethanesulfonate, and ethanesulfonate, aryl sulfonates such as benzenesulfonate and p-toluenesulfonate, organic acid salts such as acetate, malate, fumarate, succinate, citrate, tartrate, oxalate, and maleate; and amino acid salts such as glycine, lysine, arginine, ornithine, glutamate, and aspartate.

[0109] In the present specification, the term "pharmacologically acceptable salt thereof" refers to a salt of an oligonucleotide containing at least one nucleoside structure represented by formula (II) of the present invention. Examples of such salts include alkali metal salts such as sodium salts, potassium salts, and lithium salts, alkaline earth metal salts such as calcium salts and magnesium salts, metal salts such as aluminum salts, iron salts, zinc salts, copper salts, nickel salts, and cobalt salts; inorganic salts such as ammonium salts, tert-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucosamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N′-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzyl-phenethylamine salts, piperazine salts, tetramethylammonium salts, tris(hydroxymethyl) Amine salts such as organic salts such as (amino)methane salts; amine salts such as hydrohalides such as hydrofluorides, hydrochlorides, hydrobromides, and hydroiodides, inorganic acid salts such as nitrates, perchlorates, sulfates, and phosphates; organic acid salts such as lower alkane sulfonates such as methanesulfonates, trifluoromethanesulfonates, and ethanesulfonates, aryl sulfonates such as benzenesulfonates and p-toluenesulfonates, acetates, malates, fumarates, succinates, citrates, tartrates, oxalates, and maleates; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamate, and aspartate.

[0110] Hereinafter, the present invention will be described in detail.

[0111] The 5'-modified nucleoside of the present invention is a compound represented by the following formula (I) or a salt thereof:

[0112]

[0113] (In formula (I),

[0114] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0115] R 1 and R 2 Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 [Where R 9 and R 10 [respectively independently represent a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms],

[0116] R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms,

[0117] R 5 and R 6 is a hydrogen atom, or R 5 and R 6 Together they form a single bond,

[0118] R 7 is a hydrogen atom, and R8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 [Where R 11 a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0119] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0120] In the above formula (I), "Base" is, for example, a purine base (i.e., purine-9-yl) or a pyrimidine base (i.e., 2-oxo-1,2-dihydropyrimidin-1-yl). These bases may have one or more substituents selected from the group consisting of a hydroxyl group, a linear alkyl group having 1 to 6 carbon atoms, a linear alkoxy group having 1 to 6 carbon atoms, a mercapto group, a linear alkylthio group having 1 to 6 carbon atoms, an amino group, a linear alkylamino group having 1 to 6 carbon atoms, and an α group consisting of a halogen atom.

[0121] Specific examples of the above-mentioned "Base" include adenine, guanine, cytosine, uracil, and thymine, as well as 6-aminopurine-9-yl, 2,6-diaminopurine-9-yl, 2-amino-6-chloropurine-9-yl, 2-amino-6-fluoropurine-9-yl, 2-amino-6-bromopurine-9-yl, 2-amino-6-hydroxypurine-9-yl, 6-amino-2-methoxypurine-9-yl, 6-amino-2-chloropurine-9-yl, 6-amino-2-fluoropurine-9-yl, 2,6-dimethoxypurine-9-yl, 2,6-dichloropurine-9-yl, 6-mercaptopurine-9-yl, Purin-9-yl, 2-oxo-4-amino-1,2-dihydropyrimidin-1-yl, 4-amino-2-oxo-5-fluoro-1,2-dihydropyrimidin-1-yl, 4-amino-2-oxo-5-chloro-1,2-dihydropyrimidin-1-yl, 2-oxo-4-methoxy-1,2-dihydropyrimidin-1-yl, 2-oxo-4-mercapto-1,2-dihydropyrimidin-1-yl, 2-oxo-4-hydroxy-1,2-dihydropyrimidin-1-yl, 2-oxo-4-hydroxy-5-methyl-1,2-dihydropyrimidin-1-yl, and 4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl.

[0122] Alternatively, from the viewpoint of introduction into nucleic acid medicines, "Base" is preferably a group represented by the following structural formula, 2-oxo-4-hydroxy-5-methyl-1,2-dihydropyrimidin-1-yl, 2-oxo-4-amino-1,2-dihydropyrimidin-1-yl, 6-aminopurin-9-yl, 2-amino-6-hydroxypurin-9-yl, 4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl, and 2-oxo-4-hydroxy-1,2-dihydropyrimidin-1-yl. "Base" is also preferably a group in which the hydroxyl group and the amino group constituting the above group are protected by a protecting group when synthesizing an oligonucleotide.

[0123]

[0124] The 5'-modified nucleoside of the present invention has a 5-membered ring structure such as a cyclopentene structure or a cyclopentane structure at the 5'-position of formula (I). By having such a structure, the nucleoside of the present invention does not have a diastereoisomer structure at the 5'-position, and compared with conventional artificial nucleic acids having a substituent introduced at the 5'-position, it is not necessary to separate diastereomers during the synthesis thereof.

[0125] Here, in one embodiment, in the above formula (I), R 5 and R 6 From the viewpoint of combination, examples of the above formula (I) include:

[0126]

[0127]

[0128] (In formula (Ia) and (Ib), Base, R 1 , R 2 , R 3 , R 4 , R 7 and R 8 The meaning is the same as that defined in the above formula (I). In addition, as more specific examples of the above formula (I), the following can be cited:

[0129]

[0130] (In formula (Ia′) and (Ib′), Base, R 1 , R 2 , R 7 and R 8 The meaning is the same as that defined in the above formula (I). In addition, in the present specification, the compound represented by the above formula (Ia') may be referred to as "5'-cp2 (modified nucleic acid)", and the compound represented by the above formula (Ib') may be referred to as "5'-cp3 (modified nucleic acid)".

[0131] Alternatively, in one embodiment, in the above formula (I), R 7 and R 8 From the viewpoint of combination, examples of the above formula (I) include:

[0132]

[0133] (In the formula, Base, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 has the same meaning as defined in the above formula (I).

[0134] Alternatively, in one embodiment, in the above formula (I), R 5 , R 6 , R 7 and R 8 From the viewpoint of combination, examples of the above formula (I) include:

[0135]

[0136] (In the formula, Base, R 1 , R 2 , R 3 , and R 4 has the same meaning as defined in the above formula (I).

[0137] The 5′-modified nucleoside of the present invention has a 5-membered ring structure as described above introduced at the 5′-position of formula (I), thereby improving the nuclease resistance in the oligonucleotide described later. In addition, the ring strain in such a 5-membered ring structure is small, and the influence on the phosphate backbone is small. Therefore, the oligonucleotide carrying the 5′-modified nucleoside of the present invention shows excellent double-strand formation ability for the target RNA.

[0138] In the present invention, oligonucleotides can be easily produced using such 5'-modified nucleosides of formula (I), for example, by the phosphoramidite method known in the art or triphosphorylation as described in M. Kuwahara et al., Nucleic Acids Res., 2008, Vol. 36, No. 13, pp. 4257-4265.

[0139] The oligonucleotide of the present invention or a pharmacologically acceptable salt thereof (hereinafter, sometimes collectively referred to as "oligonucleotide of the present invention") comprises at least one nucleoside structure represented by the following formula (II):

[0140]

[0141] (In formula (II),

[0142] Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom,

[0143] R 3 and R 4 are each independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms,

[0144] R 5 and R 6 is a hydrogen atom, or R 5 and R 6 Together they form a single bond,

[0145] R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 [Where R 11 a protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis], or

[0146] R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-).

[0147] Among them, in one embodiment, in the above R 6 and R 7 From the viewpoint of combination, examples of the nucleoside structure of formula (II) contained in the oligonucleotide of the present invention include:

[0148]

[0149] (In formula (IIa) and (IIb), Base, R 3 , R 4 , R 7 and R 8 The meaning is the same as that defined in the above formula (I). In addition, as more specific examples of the nucleoside structure of the above formula (II) contained in the oligonucleotide of the present invention, the following can be cited:

[0150]

[0151]

[0152] (In formula (IIa') and (IIb'), Base, R 7 and R 8 has the same meaning as defined in the above formula (I).

[0153] Alternatively, in one embodiment, in the above formula (II), R 7 and R 8 From the viewpoint of combination, examples of the nucleoside structure of formula (II) contained in the oligonucleotide of the present invention include:

[0154]

[0155]

[0156] (In the formula, Base, R 3 , R 4 , R 5 and R 6 has the same meaning as defined in the above formula (I).

[0157] Alternatively, in one embodiment, in the above formula (II), R 5 , R 6 , R 7 and R 8 From the viewpoint of combination, examples of the nucleoside structure of formula (II) contained in the oligonucleotide of the present invention include:

[0158]

[0159] (In the formula, Base, R 3 and R 4 has the same meaning as defined in the above formula (I).

[0160] The oligonucleotide of the present invention has at least one of the above-mentioned nucleoside structures at any position. The position and number thereof are not particularly limited and can be appropriately designed according to the purpose.

[0161] Oligonucleotides (antisense molecules) containing such nucleoside structures have a dramatic improvement in nuclease resistance compared to the 2′,4′-BNA / LNA used in the past. In addition, they have an appropriate ability to form double strands for target RNA. In addition, the oligonucleotides can also reduce hepatotoxicity without impairing antisense activity.

[0162] Therefore, the oligonucleotide of the present invention synthesized using the above-mentioned 5'-modified nucleoside can be expected to be useful as a pharmaceutical (antisense molecule) for treating diseases, such as antitumor agents and antiviral agents, by inhibiting or restoring the action of specific genes. Examples of pharmaceuticals that can be expected to have such usefulness include drugs for treating muscular dystrophy.

[0163] In particular, in the antisense method, both binding affinity (double-strand forming ability) to complementary positive strand RNA and resistance to nucleic acid degrading enzymes (nucleases) in the body are required. In particular, imparting resistance to nucleases is essential in the pharmaceuticalization of nucleic acid molecules. The 5′-modified nucleic acid of the present invention has a nuclease resistance equal to or higher than that of the phosphorothioate modified nucleic acid currently used in the development of nucleic acid medicines, and is expected to be used as a substitute for the phosphorothioate modified nucleic acid that has been pointed out to be associated with hepatotoxicity.

[0164] The oligonucleotide of the present invention can be prepared into a non-oral preparation or a liposome preparation by combining, for example, excipients, binders, preservatives, oxidative stabilizers, disintegrants, lubricants, flavoring agents and other adjuvants commonly used in the field of pharmaceutical preparation technology. In addition, for example, it can be prepared into a topical preparation such as a liquid, cream, or ointment by combining with a pharmaceutical carrier commonly used in the field of the technology.

[0165] Example

[0166] Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.

[0167] (Example 1: Synthesis of 5′-modified nucleosides (1))

[0168]

[0169] Reagents and conditions for each process: (a) Allyl magnesium bromide CeCl3, THF, room temperature, 22 hours, 82%; (b) Second-generation Grubbs catalyst, DCM, 40°C, 5 hours, 96%; (c) Pd(OH)2 / C, H2, AcOEt, room temperature, 0.5 hours, 83%; (d) TrOTf, 2,6-dimethylpyridine, 80°C, 39 hours, 67%; (e) TBAF, THF, room temperature, 39 hours, 87%; (f) iPr2NP(Cl)OCH2CH2CN, DIPEA, MeCN, room temperature, 14 hours, 63%.

[0170] (1-1) Synthesis of Compound 2

[0171]

[0172] Cerium (III) chloride (1287 mg, 5.22 mmol) was added to compound 1 (500 mg, 1.30 mmol) obtained by the method described in the above-mentioned patent document 4 (International Publication No. 2020 / 158910), and anhydrous tetrahydrofuran (13 mL) was added to form a suspension after toluene azeotropy. 1.0 M allyl magnesium bromide-diethyl ether solution (5.2 mL, 5.2 mmol) was added dropwise at room temperature under a nitrogen stream. After the addition, it was stirred for another hour. After the reaction was completed, a saturated aqueous solution of ammonium chloride was added, filtered through diatomaceous earth, and the filtrate was extracted with ethyl acetate. After washing the organic layer with water and saturated brine, it was dried over anhydrous sodium sulfate and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, hexane: ethyl acetate = 2: 1) to obtain compound 2 (463 mg, 82%) as a yellow solid. The physical property data of the obtained compound 2 are shown in Table 1.

[0173] [Table 1]

[0174]

[0175] (1-2) Synthesis of Compound 3

[0176]

[0177] Under nitrogen flow, the second generation Grubbs catalyst (71.6 mg, 0.0840 mmol) was added to the deoxygenated dichloromethane solution (56 mL) of the compound 2 obtained above. After stirring at 40°C for 3 hours, the dichloromethane was removed by reduced pressure distillation, and the obtained crude product was purified by silica gel column chromatography (SiO2, hexane: ethyl acetate = 3: 2) to obtain compound 3 (660 mg, 96%) as a white solid. The physical property data of the obtained compound 3 are shown in Table 2.

[0178] [Table 2]

[0179]

[0180] (1-3) Synthesis of Compound 4

[0181]

[0182] Palladium hydroxide-activated carbon (Pd20%) (100 mg, 50 wt%) was added to the ethyl acetate solution (4.9 mL) of the compound 3 obtained above (200 mg, 0.488 mmol). The flask was replaced with hydrogen, and the reaction solution was stirred at room temperature for 0.5 hours. After the reaction was completed, the reaction solution was filtered and the ethyl acetate was removed by vacuum distillation. The obtained residue was purified by silica gel column chromatography (SiO2, hexane: ethyl acetate = 3: 2) to obtain compound 4 (166 mg, 83%) as a white solid. The physical property data of the obtained compound 4 are shown in Table 3.

[0183] [Table 3]

[0184]

[0185] (1-4) Synthesis of Compound 5

[0186]

[0187] Silver trifluoromethanesulfonate (2060 mg, 8.02 mmol) was added to a solution of triphenylchloromethane (2242 mg, 8.04 mmol) in anhydrous dichloromethane (13 mL) and mixed. The orange suspension was stirred at room temperature for 3 hours, and silver chloride was precipitated. The supernatant trityl trifluoromethanesulfonate solution (6 mL) was added to a solution of compound 4 (488 mg, 1.19 mmol) in anhydrous 2,6-lutidine (6 mL) at 0°C. After stirring at 80°C for 39 hours, a saturated aqueous sodium bicarbonate solution was added to the reaction solution. A saturated aqueous copper sulfate solution was then added to emulsify the lutidine, and then filtered with diatomaceous earth using ethyl acetate. The solvent was removed by vacuum distillation, and the residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, hexane: ethyl acetate = 7:3) to obtain compound 5 (523 mg, 67%) as a yellow solid. Table 4 shows the physical property data of the obtained compound 5.

[0188] [Table 4]

[0189]

[0190] (1-5) Synthesis of Compound 6

[0191]

[0192] 1.0M tetrabutylammonium fluoride-tetrahydrofuran solution (345 μL, 0.345 mmol) was added to the tetrahydrofuran solution (3.8 mL) of the compound 5 obtained above, and stirred at room temperature for 39 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, chloroform: methanol = 30: 1 → hexane: ethyl acetate = 1: 1) to obtain compound 6 (161 mg, 87%) as a white solid. The physical property data of the obtained compound 6 are shown in Table 5.

[0193] [Table 5]

[0194]

[0195] (1-6) Synthesis of Compound 7 (Phosphoramidite Building Block 7)

[0196]

[0197] Under nitrogen flow, N,N-diisopropylethylamine (400 μL, 2.30 mmol) and 2-cyanoethyl-N,N-diisopropyl chlorophosphate (245 μL, 1.10 mmol) were added to a solution of compound 6 (397 mg, 0.737 mmol) in anhydrous acetonitrile (7.4 mL) at 0°C in sequence, and the mixture was stirred at room temperature for 2.5 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, hexane: ethyl acetate = 3:2). Furthermore, compound 7 (344 mg, 63%, diastereoisomer ratio 3:2) was obtained as a white solid by reprecipitation (toluene / hexane). The physical property data of the obtained compound 7 are shown in Table 6.

[0198] [Table 6]

[0199]

[0200] (Example 2: Synthesis of 5′-modified nucleosides (2))

[0201]

[0202] Reagents and conditions for each step: (g) TESCl, pyridine, room temperature, 1 hour, 82%; (h) 1,2,4-triazole, POCl3, DCM, room temperature, 2.5 hours; 28% NH3 water, 1,4-dioxane, room temperature, 2.5 hours, 93%; (i) Bz2O, pyridine, room temperature, 16 hours, 97%; (j) TBAF, THF, room temperature, 1 hour, 76%; (k) iPr2NP(Cl)OCH2CH2CN, DIPEA, DCM, room temperature, 5.5 hours, 83%.

[0203] (2-1) Synthesis of Compound 8

[0204]

[0205] Under nitrogen flow, triethylsilyl chloride (320 μL, 2.48 mmol) was added to a pyridine solution (6.2 mL) of the compound 6 (333 mg, 0.618 mmol) obtained above, and stirred at room temperature for 1 hour. After the reaction was completed, a saturated sodium bicarbonate aqueous solution was added, extracted with ethyl acetate, washed with water and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, hexane: ethyl acetate = 3: 1) to obtain compound 8 (332 mg, 82%) as a white solid. The physical property data of the obtained compound 8 are shown in Table 7.

[0206] [Table 7]

[0207]

[0208] (2-2) Synthesis of Compound 9

[0209]

[0210] Under nitrogen flow, triethylamine (160 μL, 1.15 mmol), 1,2,4-triazole (79 mg, 1.15 mmol), and phosphorus oxychloride (21 μL, 0.230 mmol) were added to a solution of compound 8 (50 mg, 0.0766 mmol) in anhydrous dichloromethane (760 μL) at 0°C in sequence, and stirred for 2.5 hours. After the reaction was completed, saturated sodium bicarbonate aqueous solution was added, extracted with ethyl acetate, washed with water and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Then, 1,2-dioxane (760 μL) and 28% ammonia water (95 μL, 1.53 mmol) were added, and stirred at room temperature for 2.5 hours. After the reaction was completed, the reaction solution was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, chloroform:methanol=50:1) to obtain compound 9 (46.4 mg, 93%) as a white solid. The physical property data of the obtained compound 9 are shown in Table 8.

[0211] [Table 8]

[0212]

[0213] (2-3) Synthesis of Compound 10

[0214]

[0215] Under nitrogen flow, anhydrous benzoyl (176 mg, 0.778 mmol) was added to a pyridine solution (5.1 mL) of the compound 9 obtained above (331 mg, 0.508 mmol), and the mixture was stirred at room temperature for 14 hours. After the reaction was completed, a saturated sodium bicarbonate aqueous solution was added, extracted with ethyl acetate, washed with water and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, hexane: ethyl acetate = 11: 1) to obtain compound 10 (373 mg, 97%) as a white solid. The physical property data of the obtained compound 10 are shown in Table 9.

[0216] [Table 9]

[0217]

[0218] (2-4) Synthesis of Compound 11

[0219]

[0220] 1.0M tetrabutylammonium fluoride-tetrahydrofuran solution (208 μL, 0.208 mmol) was added to the tetrahydrofuran solution (2.4 mL) of the compound 10 obtained above, and stirred at room temperature for 1 hour. After the reaction was completed, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, hexane: ethyl acetate = 3: 1) to obtain compound 11 (105 mg, 79%) as a white solid. The physical property data of the obtained compound 11 are shown in Table 10.

[0221] [Table 10]

[0222]

[0223] (2-5) Synthesis of Compound 12 (Phosphoramidite Building Block 12)

[0224]

[0225] Under nitrogen flow, N,N-diisopropylethylamine (86 μL, 0.741 mmol) and 2-cyanoethyl-N,N-diisopropyl chlorophosphate (82 μL, 0.378 mmol) were added to an anhydrous dichloromethane solution (1.6 mL) of the compound 11 obtained above (105 mg, 0.164 mmol) at 0°C in sequence, and stirred at room temperature for 5.5 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, hexane: ethyl acetate = 3: 1) to obtain compound 12 (115 mg, 83%, diastereoisomer ratio 1: 1) as a white solid. The physical property data of the obtained compound 12 are shown in Table 11.

[0226] [Table 11]

[0227]

[0228] (Example 3: Synthesis of 5′-modified nucleosides (3))

[0229]

[0230] Reagents and conditions for each step: (l) TrOTf, 2,6-dimethylpyridine, 80°C, 22.5 hours, 80%; (m) TBAF, THF, room temperature, 22.5 hours, quantitative (quant.); (n) iPr2NP(Cl)OCH2CH2CN, DIPEA, MeCN, room temperature, 1.25 hours, 76%.

[0231] (3-1) Synthesis of Compound 13

[0232]

[0233] Silver trifluoromethanesulfonate (1152 mg, 4.48 mmol) was added to a solution of triphenylchloromethane (1254 mg, 4.50 mmol) in anhydrous dichloromethane (7.3 mL) and mixed. The orange suspension was stirred at room temperature for 1.5 hours to precipitate silver chloride. The supernatant trityl trifluoromethanesulfonate solution (3.6 mL) was added to a solution of compound 3 (300 mg, 0.734 mmol) in anhydrous 2,6-lutidine (3.6 mL) at 0°C. After stirring at 80°C for 22.5 hours, a saturated aqueous sodium bicarbonate solution was added to the reaction solution. A saturated aqueous copper sulfate solution was then added to emulsify the lutidine, and then filtered with diatomaceous earth using ethyl acetate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, hexane: ethyl acetate = 5:1→7:3) to obtain compound 13 (382 mg, 80%) as a yellow solid. Table 12 shows the physical property data of the obtained compound 13.

[0234] [Table 12]

[0235]

[0236] (3-2) Synthesis of Compound 14

[0237]

[0238] To the tetrahydrofuran solution (5.5 mL) of the compound 13 obtained above (218 mg, 0.335 mmol), 1.0 M tetrabutylammonium fluoride-tetrahydrofuran solution (335 μL, 0.335 mmol) was added and stirred at room temperature for 19 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, chloroform: methanol = 15: 1) to obtain compound 14 (180 mg, quantitative) as a white solid. The physical property data of the obtained compound 14 are shown in Table 13.

[0239] [Table 13]

[0240]

[0241] (3-3) Synthesis of Compound 15 (Phosphoramidite Building Block 15)

[0242]

[0243] Under nitrogen flow, N,N-diisopropylethylamine (290 μL, 1.66 mmol) and 2-cyanoethyl-N,N-diisopropyl chlorophosphate (190 μL, 0.852 mmol) were added to a solution of compound 14 (300 mg, 0.559 mmol) in anhydrous acetonitrile (5.6 mL) at 0°C in sequence, and the mixture was stirred at room temperature for 1.25 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, hexane: ethyl acetate = 2:1). Furthermore, compound 15 (306 mg, 76%, diastereoisomer ratio 1:1) was obtained as a white solid by reprecipitation (toluene / hexane). The physical property data of the obtained compound 15 are shown in Table 14.

[0244] [Table 14]

[0245]

[0246] (Example 4: Synthesis of 5′-Modified Nucleosides (4))

[0247]

[0248] Reagents and conditions for each step: (o)N 2 -isobutyrylguanine, TMSOTf, BSA, toluene, 80°C, 2 hours, 39%; (p) TBAF, THF, 50°C, 6.5 hours, 95%; (q) iPr2NP(Cl)OCH2CH2CN, DIPEA, DCM, room temperature, 5 hours, 52%.

[0249] (4-1) Synthesis of Compound 16

[0250]

[0251] Under nitrogen flow, N 2-isobutyrylguanine (381 mg, 1.73 mmol) and N,O-bis(trimethylsilyl)acetamide (2.0 mL, 8.05 mmol) were added, and trimethylsilyl trifluoromethane ester (21 μL, 0.115 mmol) was added at 0°C, and stirred at 80°C for 2 hours. After the reaction was completed, a saturated aqueous sodium bicarbonate solution was added, and the insoluble matter was removed by filtration through diatomaceous earth. It was extracted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, chloroform: methanol = 300: 1) to obtain compound 16 (332 mg, 39%) as a white solid. The physical property data of the obtained compound 16 are shown in Table 15.

[0252] [Table 15]

[0253]

[0254] (4-2) Synthesis of Compound 17

[0255]

[0256] A 1.0 M tetrabutylammonium fluoride-tetrahydrofuran solution (609 μL, 0.609 mmol) was added to a tetrahydrofuran solution (7.0 mL) of the compound 16 obtained above (456 mg, 0.609 mmol), and the mixture was stirred at 50° C. for 6.5 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (Diol Silica, containing 1.0% triethylamine, chloroform: methanol = 200: 1) to obtain compound 17 (367.3 mg, 95%) as a white solid. The physical property data of the obtained compound 17 are shown in Table 16.

[0257] [Table 16]

[0258]

[0259] (4-3) Synthesis of Compound 18 (Phosphoramidite Building Block 18)

[0260]

[0261] Under nitrogen flow, N,N-diisopropylethylamine (42 μL, 0.238 mmol) and 2-cyanoethyl-N,N-diisopropyl chlorophosphate (27 μL, 0.119 mmol) were added to a solution of compound 17 (50.3 mg, 0.0794 mmol) in anhydrous dichloromethane (794 μL) at 0°C in sequence, and the mixture was stirred at room temperature for 5 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (Diol Silica, containing 1.0% triethylamine, hexane: ethyl acetate = 1: 1). Compound 18 (34.4 mg, 52%, diastereoisomer ratio 1: 1) was obtained as a white solid by reprecipitation (chloroform / ethyl acetate). The physical property data of the obtained compound 18 are shown in Table 17.

[0262] [Table 17]

[0263]

[0264] (Example 5: Synthesis of 5′-modified nucleosides (5))

[0265]

[0266] Reagents and conditions for each step: (r)N 6 -Benzoyladenine, TMSOTf, BSA, toluene, 80°C, 1.5 hours, 28%; (s) TBAF, THF, 50°C, 3.5 hours, quantitative; (t) iPr2NP(Cl)OCH2CH2CN, DIPEA, DCM, room temperature, 5 hours, 51%.

[0267] (5-1) Synthesis of Compound 19

[0268]

[0269] Under nitrogen flow, N 6-benzoyladenine (501 mg, 2.10 mmol) and N,O-bis(trimethylsilyl)acetamide (2.1 mL, 8.38 mmol) were added, and trimethylsilyl trifluoroformate (25 μL, 0.140 mmol) was added at 0°C, and stirred at 80°C for 1.5 hours. After the reaction was completed, a saturated aqueous sodium bicarbonate solution was added, and the insoluble matter was removed by filtration through diatomaceous earth. Extracted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, containing 0.5% triethylamine, chloroform) to obtain compound 19 (303 mg, 28%) as a white solid. The physical property data of the obtained compound 19 are shown in Table 18.

[0270] [Table 18]

[0271]

[0272] (5-2) Synthesis of Compound 20

[0273]

[0274] A 1.0M tetrabutylammonium fluoride-tetrahydrofuran solution (199 μL, 0.199 mmol) was added to a tetrahydrofuran solution (2.3 mL) of the compound 19 obtained above, and the mixture was stirred at 50°C for 3.5 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (Diol Silica, containing 1.0% triethylamine, hexane: ethyl acetate = 1: 1 → chloroform) to obtain compound 20 (130 mg, quantitative) as a white solid. The physical property data of the obtained compound 20 are shown in Table 19.

[0275] [Table 19]

[0276]

[0277] (5-3) Synthesis of Compound 21 (Phosphoramidite Building Block 21)

[0278]

[0279] Under nitrogen flow, N,N-diisopropylethylamine (41 μL, 0.233 mmol) and 2-cyanoethyl-N,N-diisopropyl chlorophosphate (26 μL, 0.117 mmol) were added to a solution of compound 20 (50.7 mg, 0.0778 mmol) in anhydrous dichloromethane (778 μL) at 0°C in sequence, and stirred at room temperature for 5 hours. After the reaction was completed, water was added, extracted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (Diol Silica, containing 1.0% triethylamine, hexane: ethyl acetate = 3:2). Further, compound 21 (34.0 mg, 51%, diastereoisomer ratio 3:2) was obtained as a white solid by reprecipitation (ethyl acetate / hexane). The physical property data of the obtained compound 21 are shown in Table 20.

[0280] [Table 20]

[0281]

[0282] (Example 6) Synthesis and purification of oligonucleotides

[0283] In order to synthesize the oligonucleotides used in the examples described below, the phosphoramidite building blocks 7, 15, 18 and 21 obtained above were prepared into a 0.1 M anhydrous dichloromethane solution, and the reaction was carried out under Trityl-on conditions using nS-8 Oligonucleotides Synthesizer (manufactured by Gene Design Co., Ltd.). Activator 42 (registered trademark) (0.25 M acetonitrile solution) was used as the activator, and the condensation time was extended to 240 seconds × 4 for phosphoramidite building blocks 7, 15, 18 and 21 and the phosphoramidite introduced subsequently. The capping time was set to 200 seconds. In addition, the deblocking time was also extended to 150 seconds × 2. The other operations were synthesized according to the conventional phosphoramidite method known per se. After the synthesis was completed, a 23% ammonia aqueous solution was used to treat at room temperature for 4 hours, cut out from the column support, and then allowed to stand at 55°C for more than 5 hours to perform deprotection. Next, the product was purified by removing the trityl group using a simple reverse phase column (Sep-Pak (registered trademark) Plus C18 Environmental Cartridges manufactured by Waters Corporation), and further purified by reverse phase HPLC.

[0284] (Example 7) Composition confirmation and quantification

[0285] After drying the matrix (10 mg / mL 3-hydroxypicolinic acid aqueous solution: 1 mg / mL diammonium citrate aqueous solution = 1:1, 1 μL), an oligonucleotide aqueous solution (50 μM, 1 μL) was placed on the AnchorChip, which was dried again, and the composition of the oligonucleotide was confirmed by MALDI-TOF MS. The molecular weight was measured in negative ion mode, using oligothymidylic acid (7mer, 9mer, 11mer and 13mer) as an external standard. In addition, the quantification of the oligonucleotide was performed by using an absorbance meter and measuring the ultraviolet external absorption at 260 nm.

[0286] (Example 8) Melting temperature (T m )

[0287] A mixture of each oligonucleotide (final concentration 4 μM) and sodium chloride (final concentration 100 mM) in phosphate buffer (10 mM, pH 7.2, 130 μL) was placed in a boiling water bath and slowly cooled to room temperature. Then, it was cooled to 5°C under a nitrogen stream and the measurement was started. The temperature was raised to 90°C at 0.5°C / min, and the absorbance at 260 nm was plotted at 0.5°C intervals. m The value was calculated by the midline method, and the average value of three independent measurements was taken. The results are shown in Table 21. In (I) of Table 21, the sequence of ssRNA is 5′-r(AGCAAAAAACGC)-3′ (sequence number 19), and regarding the superscript characters 1 to 3, 1 represents 5′-cp, 2 represents 5′-cp2, and 3 represents 5′-cp3. In (II) of Table 21, the sequence of ssRNA is 5′-r(AGCAAAGAACGC)-3′ (sequence number 26), m C cp3 In (III) of Table 21, the sequence of ssRNA is 5′-r(AGCAAAUAACGC)-3′ (SEQ ID NO: 27), A cp3 In (IV) of Table 21, the sequence of ssRNA is 5′-r(AGCAAACAACGC)-3′ (SEQ ID NO: 28), G cp3 It is 5′-cp3-guanine.

[0288] [Table 21]

[0289]

[0290] T 1 :5′-cp-thymine, T 2 :5′-cp2-thymine, T 3 :5′-cp3-thymine, m C cp3:5′-cp3-5-methylcytosine, A cp3 :5′-cp3-adenine, G cp3 :5′-cp3-guanine

[0291] As can be seen from Table 21, the T of the oligonucleotide carrying the existing artificial nucleic acid shown in SEQ ID NO: 2 is m Compared with the values, the T values ​​of the oligonucleotides carrying the artificial nucleic acids of the present invention shown in SEQ ID NOs. 3 and 4 were m From this result, it can be seen that the artificial nucleic acid having 5′-cp2 and 5′-cp3 of the present invention has higher and more excellent ability to form a double strand of RNA than the conventional artificial nucleic acid having 5′-cp.

[0292] (Example 9) Enzyme resistance evaluation

[0293] 1.5 μg / mL of 3′-exonuclease (snake venom phosphodiesterase, svPDE) was added to 50 mM Tris-HCl buffer (pH 8.0) containing 7.5 μM oligonucleotide and 10 mM magnesium chloride, and incubated at 37°C. 10 μL of sample was taken at 0, 2.5, 5.0, 10, 20 and 40 minutes, and the proportion of uncut oligonucleotide was calculated by reverse phase HPLC analysis. In addition, the evaluation was derived by 3 independent measurements. The oligonucleotides used in this evaluation are shown in Table 22.

[0294] [Table 22]

[0295]

[0296] T 1 :5′-cp-thymine, T 2 :5′-cp2-thymine, T 3 :5′-cp3-thymine,

[0297] ^: Phosphorothioate (PS)

[0298] From this experiment, it was found that the oligonucleotides carrying the artificial nucleic acid of the present invention shown in sequence numbers 10 and 11 were more stable against 3′-exonucleases than the phosphorothioate (PS)-modified nucleic acid commonly used in nucleic acid drugs shown in sequence number 8 ( Figure 1 ).

[0299] (Example 10) Animal Test

[0300] The test oligonucleotide (100 nmol) was administered to 6-week-old mice (C57BL / 6NCrl, male: purchased from The Jackson Laboratory Japan, Inc.) through the tail vein (n=5). As a control, physiological saline was administered. After 96 hours, blood was collected under inhalation anesthesia (isofluorane) and the mice were euthanized by exsanguination. Then, various organs were collected, and the liver weight was measured and RNA was extracted (RNeasy Mini Kit: manufactured by QIAGEN). The activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the blood were measured by an automatic analyzer (TBA-2000FR manufactured by Canon Medical Systems, Inc.). In addition, the mRNA expression levels of the target gene GR (NR3C1) and the housekeeping gene GAPDH were measured by real-time PCR (using the kit: One Step PrimeScript RT-PCR Kit (manufactured by Takara Bio Co., Ltd.), primer sequences: NR3C1 forward (actgtccagcatgccgctat) (sequence number 12), NR3C1 reverse (gcagtggcttgctgaattcc) (sequence number 13), GAPDH forward (gtgtgaacggatttggccgt) (sequence number 14), GAPDH reverse (gacaagcttcccattctcgg) (sequence number 15)).

[0301] [Table 23]

[0302] Test oligonucleotides:

[0303]

[0304] T :5′-cp3-T, L G:LNA-G, L C:LNA- m C, L T:LNA-T,^:Phosphorothioate (PS)

[0305] (Results of target gene inhibition effect)

[0306] From this experiment, it can be seen that the antisense effect of the oligonucleotides carrying the artificial nucleic acid of the present invention shown in SEQ ID NOs. 17 and 18 is equal to or better than that of the phosphorothioate (PS) modified sequence commonly used in nucleic acid drugs shown in SEQ ID NO. 16, and can serve as a substitute for the commonly used PS modification ( Figure 2 ). In addition, it can be seen that compared with general PS modification, it can exert a more excellent antisense effect in the liver, large intestine and skeletal muscle ( Figure 2 ).

[0307] (AST / ALT evaluation results)

[0308] Regarding AST (U / L) and ALT (U / L), which are indicators of hepatotoxicity, it was found that the levels of AST (U / L) and ALT (U / L) were significantly reduced when the oligonucleotides carrying the artificial nucleic acid of the present invention represented by SEQ ID NOs. 17 and 18 were used, compared with the phosphorothioate (PS)-modified sequence commonly used in nucleic acid pharmaceuticals represented by SEQ ID NO: 16 ( Figure 3 ). From this result, it can be understood that, compared with the sequences modified with phosphorothioate (PS) commonly used in pharmaceuticals, the toxicity of the artificial nucleic acid of the present invention and the oligonucleotide carrying the artificial nucleic acid to the organism is suppressed and the desired antisense effect can be exerted.

[0309] Industrial Applicability

[0310] The oligonucleotide obtained using the 5'-modified nucleoside of the present invention is useful as a raw material for nucleic acid medicine, for example.

Claims

1. A compound represented by the following formula (I) or a salt thereof: In formula (I), Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the group α, wherein The α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom. R 1 and R 2 Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 , formula -P(R 9 )R 10 In, R 9 and R 10 Each independently represents a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms, R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms, R 5 and R 6 is a hydrogen atom, or R 5 and R 6 Together they form a single bond, R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 , formula -OR 11 In, R 11 A protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis, or R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-.

2. The compound or salt thereof according to claim 1, characterized in that: The formula (I) is represented by the following formula (Ia): In formula (Ia), Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom, R 1 and R 2 Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 , formula -P(R 9 )R 10 In, R 9 and R 10 Each independently represents a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms, R 3 and R 4 are each independently a hydrogen atom or an alkyl group having 1 or 2 carbon atoms, R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 , formula -OR 11 In, R 11 A protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis, or R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-.

3. The compound or salt thereof according to claim 1, characterized in that: The formula (I) is represented by the following formula (Ib): In formula (Ib), Base represents a purine-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom, R 1 and R 2 Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 , formula -P(R 9 )R 10 In, R 9 and R 10 each independently represents a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms, R 3 and R 4 are each independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms, R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 , formula -OR 11 In, R 11 A protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis, or R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-.

4. The compound or salt thereof according to claim 1, characterized in that: In the formula (I), the Base is 6-aminopurine-9-yl, 2,6-diaminopurine-9-yl, 2-amino-6-chloropurine-9-yl, 2-amino-6-fluoropurine-9-yl, 2-amino-6-bromopurine-9-yl, 2-amino-6-hydroxypurine-9-yl, 6-amino-2-methoxypurine-9-yl, 6-amino-2-chloropurine-9-yl, 6-amino-2-fluoropurine-9-yl, 2,6-dimethoxypurine-9-yl, 2,6-dichloropurine-9-yl, 6-mercaptopurine-9-yl, 2-oxo-4-aminopurine 4-amino-2-oxo-5-fluoro-1,2-dihydropyrimidin-1-yl, 4-amino-2-oxo-5-chloro-1,2-dihydropyrimidin-1-yl, 2-oxo-4-methoxy-1,2-dihydropyrimidin-1-yl, 2-oxo-4-mercapto-1,2-dihydropyrimidin-1-yl, 2-oxo-4-hydroxy-1,2-dihydropyrimidin-1-yl, 2-oxo-4-hydroxy-5-methyl-1,2-dihydropyrimidin-1-yl, or 4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl.

5. The compound or salt thereof according to claim 1, characterized in that: In the formula (I), the Base is a group represented by the following formula:

6. An oligonucleotide or a pharmacologically acceptable salt thereof, comprising at least one nucleoside structure represented by the following formula (II): In formula (II), Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the group α, wherein The α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom. R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms, R 5 and R 6 is a hydrogen atom, or R 5 and R 6 Together they form a single bond, R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 , formula -OR 11 In, R 11 A protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis, or R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-.

7. The oligonucleotide or pharmacologically acceptable salt thereof according to claim 6, characterized in that: The formula (II) is represented by the following formula (IIa): In formula (IIa), Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom, R 3 and R 4 are each independently a hydrogen atom or an alkyl group having 1 or 2 carbon atoms, R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 , formula -OR 11 In, R 11 A protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis, or R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-.

8. The oligonucleotide or pharmacologically acceptable salt thereof according to claim 6, characterized in that: The formula (II) is represented by the following formula (IIb): In formula (IIb), Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom, R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms, R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 , formula -OR 11 In, R 11 A protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis, or R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-.

9. The method for producing an oligonucleotide or a pharmacologically acceptable salt thereof according to claim 6, characterized in that: The method comprises the step of synthesizing an oligonucleotide using a compound represented by the following formula (I) or a salt thereof, In formula (I), Base represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group which may have one or more substituents selected from the α group, wherein the α group includes a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a straight-chain alkyl group having 1 to 6 carbon atoms, a straight-chain alkoxy group having 1 to 6 carbon atoms, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, a straight-chain alkylthio group having 1 to 6 carbon atoms, an amino group, a straight-chain alkylamino group having 1 to 6 carbon atoms, an amino group protected by a protecting group for nucleic acid synthesis, and a halogen atom, R 1 and R 2 Each independently represents a hydrogen atom, a protecting group for a hydroxyl group used in nucleic acid synthesis, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, an alkenyl group having 2 to 7 carbon atoms which may form a branch or a ring, an aryl group having 3 to 10 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an aralkyl group including an aryl moiety having 3 to 12 carbon atoms which may have one or more substituents selected from the α group and may contain a heteroatom, an acyl group which may have one or more substituents selected from the α group, a silyl group which may have one or more substituents selected from the α group, a phosphate group which may have one or more substituents selected from the α group, a phosphate group protected by a protecting group used in nucleic acid synthesis, -P(R 9 )R 10 , formula -P(R 9 )R 10 In, R 9 and R 10 Each independently represents a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or a dialkylamino group having an alkyl group having 1 to 6 carbon atoms, R 3 and R 4 are independently a hydrogen atom, a hydroxyl group, a hydroxyl group protected by a protective group for nucleic acid synthesis, an amino group, an amino group protected by a protective group for nucleic acid synthesis, or an alkyl group having 1 or 2 carbon atoms, R 5 and R 6 is a hydrogen atom, or R 5 and R 6 Together they form a single bond, R 7 is a hydrogen atom, and R 8 is a hydrogen atom, a halogen atom; a straight-chain alkoxy group having 1 to 6 carbon atoms which may be substituted with a straight-chain alkoxy group having 1 to 6 carbon atoms; or -OR 11 , formula -OR 11 In, R 11 A protecting group for a hydrogen atom or a hydroxyl group in nucleic acid synthesis, or R 7 and R 8 Together they represent a divalent group represented by -CH2O- or -OCH2-.